A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma.

Disease Sites:

Pediatrics

Staging:

Phase III

Age Group:

Both

Therapies:

Chemotherapy - cytotoxic, Mol. targeted/Immunotherapy/Biologics

Drugs:

Cyclophosphamide (CPM), Dactinomycin (actinomycin-D), Mesna, Vincristine

Principal Investigator(s):

Borinstein, Scott

Scope:

International

Participating Institutions:

Vanderbilt University

Open Date:

12-20-2022

Trial Type:

Treatment

Protocol ID:

COGARST2032

National Clinical Trial ID:

NCT05304585

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available